Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women

Wu, Xian-Ping; Wu, Xianping; Xie, Hui; Zhang, H.; Peng, Yangyang; Yuan, Ling‐Qing; Su, Xianwei; Luo, Xi; Liao, Er-Yuan

doi:10.1007/s00198-009-0943-9

Cited by 44 publications

(38 citation statements)

References 40 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review is focused on the diagnostic value of several new serum markers of bone metabolism, including bonespecific alkaline phosphatase (bAP. Some researchers find similar results to ours, their studies have highlighted the correlation between the BAP and the sexual hormones during menopause; they showed that the concentration of BAP is related to the concentration of the follicle stimulating hormone (FSH) among menopausal women (13)(14)(15) . A Chinese investigation reported that the concentration of FSH explained 1.9-11.8% of BAP concentration among postmenopausal women (13).…”

Section: Discussionsupporting

confidence: 81%

Association between the bone turnover markers and the gynecologic factors among Moroccan women

Nejjar

Bour

Sfendla³

et al. 2017

AABS

View full text Add to dashboard Cite

Background:The action of bone cells on the bone mineral density can be highlighted from their enzymatic activities, by the bone alkaline phosphates (BAP) and the Cross Laps-telopeptide terminal of the collagen type 1 (β-CTX). They are reliable to explore the activity of bone turnover. We aim to put in perspective the association between gynecological factors and the concentration of bone turnover markers (BTMs) among Moroccan women.Methods: This is a cross-sectional study of 125 women from February to April 2015. A randomized sample was made. The biochemical parameters of bone metabolism concerned serum calcium, 25 hydroxyvitamin D (25OHD), parathyroid hormone (PTH), phosphorus , BAP and β-CTX. All data related to gynecologic, sociodemographic and anamnesis parameters was collected by standardized questionnaire.Result: Among 125 women, 64(51.42) were menopausal, the mean BAP was 22.1±7.6 ng/L, the median of the interval between successive births "IBSB" and of β-CTX were 36.0 [24.0-58.0] months, 368.5 [237.0-504.8]ng/L. A positive correlation was observed between the β-CTX and IBSB (r=0.2,p=0.05). The BAP concentration was higher in menopausal women (p<0.001). The linear regression showed that 12% of BAP concentration was associated to the menopause (R 2 =0.12, p=0.001) but no associated factors was founded with concentration of β-CTX. Conclusion:Our study shows that the menopause is associated factor with concentration of BAP and IBSB is correlated with the concentration of β-CTX. Keywords IntroductionThe bone remodeling is a complex physiological process during which the osteoclasts, cells of bone resorption, and the osteoblasts, cells of bone formation, act in sequential and coupled frequencies to destruct and renew the bone matrix. The objective of this physiological process is to lead an adequate bone mineral density (BMD) depending on the age and the sex (1). This bone remodeling process is under the action of several factors such as biological mediators, cited the vitamin D and the calcium, also under the action of sexual hormones and under the action of some external parameters related to the lifestyle of the person (1, 2).The action of these cells on the bone can be highlighted from their enzymatic activities by the biochemical markers of bone turnover: Bone Alkaline Phosphatase (BAP) and C-telopeptide Terminal Collagen type 1 (β-CTX). The BAP is an enzyme of the bone formation specific to the osteoblasts whereas the β-CTX is an enzyme of bone resorption specific to the osteoclasts (2). The use of these enzymes are reliable to their non invasive exploration of bone turnover (3), they allow in association with the bone densitometry to estimate the loss of bone and to monitor the response of therapeutic effect of several bone diseases (4).The trend to establish a link between markers and BMD was also subject to research among Moroccan researchers (5,6). Yet, to our knowledge, no study so far in Morocco has been undertaken to study the associated factors with the concentration of biochemical of bo...

show abstract

Section: Discussionsupporting

confidence: 81%

Association between the bone turnover markers and the gynecologic factors among Moroccan women

Nejjar

Bour

Sfendla³

et al. 2017

AABS

View full text Add to dashboard Cite

show abstract

“…The analysis of data from Chinese women showed similar trends: a high association between bone loss and high serum FSH (23,24). In a group of southern Chinese women aged between 45 and 55 y, those in the highest quartile of serum FSH lost bone at a 1.3-to 2.3-fold higher rate than those in the lowest quartile (25). Likewise, a further detailed analysis of a National Health and Nutrition Examination Survey III cohort of women between the ages of 42 and 60 y showed a strong correlation between serum FSH and femoral neck bone mineral density (26).…”

Section: Discussionmentioning

confidence: 76%

“…Clinical correlations between bone loss and serum FSH levels are now being widely recognized (2,3,6,(23)(24)(25)(26)(27)(28). Most impressive is the Study of Women's Health Across the Nations (SWAN), which showed a strong correlation between changes in serum FSH levels, elevations in bone turnover markers, and decrements in bone mineral density (2,3,6).…”

Section: Discussionmentioning

confidence: 99%

Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis

Zhu

Blair

Cao

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

136

143

View full text Add to dashboard Cite

Low estrogen levels undoubtedly underlie menopausal bone thinning. However, rapid and profuse bone loss begins 3 y before the last menstrual period, when serum estrogen is relatively normal. We have shown that the pituitary hormone FSH, the levels of which are high during late perimenopause, directly stimulates bone resorption by osteoclasts. Here, we generated and characterized a polyclonal antibody to a 13-amino-acid-long peptide sequence within the receptor-binding domain of the FSH β-subunit. We show that the FSH antibody binds FSH specifically and blocks its action on osteoclast formation in vitro. When injected into ovariectomized mice, the FSH antibody attenuates bone loss significantly not only by inhibiting bone resorption, but also by stimulating bone formation, a yet uncharacterized action of FSH that we report herein. Mesenchymal cells isolated from mice treated with the FSH antibody show greater osteoblast precursor colony counts, similarly to mesenchymal cells isolated from FSH receptor (FSHR) −/− mice. This suggests that FSH negatively regulates osteoblast number. We confirm that this action is mediated by signaling-efficient FSHRs present on mesenchymal stem cells. Overall, the data prompt the future development of an FSH-blocking agent as a means of uncoupling bone formation and bone resorption to a therapeutic advantage in humans.osteoporosis | sex steroids | skeletal anabolic | gonadotropin W omen lose over 3% of bone mass during late perimenopause at which time estrogen levels remain relatively unperturbed (1, 2). This bone loss begins 3 y before the last menstrual period (3), and arises from a profound elevation in bone resorption, which is not compensated by parallel increases in bone formation (4). Inhibiting bone resorption during this period with an anticatabolic agent, such as a bisphosphonate, selective estrogen receptor modulator, or estrogen itself, attenuates bone loss (5). However, estrogen use can be associated with increased breast cancer risk and designer estrogens have undesirable side effects. Further, growing concerns regarding oversuppression of bone turnover by bisphosphonates limit their use as early as perimenopause (5). The relatively small armamentarium for osteoporosis therapies, particularly for early and rapidly progressing bone loss, makes the advent of newer preventative strategies very desirable.A close examination of hormonal changes in women during late perimenopause shows that, whereas estrogen levels remain unperturbed, FSH levels have begun to rise, likely to compensate for failing ovaries (3). Strong correlations between rising serum FSH levels and bone loss have been documented, particularly in the Study of Women's Health Across Nations (SWAN) (2, 6). Furthermore, amenorrheic women with high FSH levels >35 IU/L display greater decrements in bone density than those with a mean FSH of ∼8 IU/L (7). Likewise, women having activating FSH receptor (FSHR) polymorphisms have a low bone mass and high bone turnover (8). Together, these findings suggest that a rising ...

show abstract

“…The Study of Women's Health Across the Nation (SWAN), a longitudinal cohort of 2375 peri-menopausal women, showed a strong correlation between serum FSH levels and markers of bone resorption, as well as an equally strong correlation between changes in FSH levels over 4 years and decrements in BMD [23]. Analyses of data from Chinese women showed similar trends: a significant association between bone loss and high serum FSH [24,25]. In a group of southern Chinese women aged between 45 and 55 years, those in the highest quartile of serum FSH lost bone at a 1.3-to 2.3-fold higher rate than those in the lowest quartile [26].…”

Section: Human Studiesmentioning

confidence: 95%

Pituitary-bone connection in skeletal regulation

Zaidi

Sun

Liu

et al. 2016

Hormone Molecular Biology and Clinical Investigation

View full text Add to dashboard Cite

Pituitary hormones have traditionally been thought to exert specific, but limited function on target tissues. More recently, the discovery of these hormones and their receptors in organs such as the skeleton suggests that pituitary hormones have more ubiquitous functions. Here, we discuss the interaction of growth hormone (GH), follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), adrenocorticotrophic hormone (ACTH), prolactin, oxytocin and arginine vasopressin (AVP) with bone. The direct skeletal action of pituitary hormones therefore provides new insights and therapeutic opportunities for metabolic bone diseases, prominently osteoporosis.

show abstract

Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women

Cited by 44 publications

References 40 publications

Association between the bone turnover markers and the gynecologic factors among Moroccan women

Association between the bone turnover markers and the gynecologic factors among Moroccan women

Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis

Pituitary-bone connection in skeletal regulation

Contact Info

Product

Resources

About